부분가수분해 구아검(PHGG) 관련 과민성 대장 증후군(IBS)
B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.IBS-C와 IBS-D 증상을 모두 줄입니다. 과도한 가스를 유발하지 않는 내약성 좋은 프리바이오틱입니다. SIBO 관련 증상에도 가능성을 보입니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dpartially\u002Dhydrolyzed\u002Dguar\u002Dgum\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
결론
IBS-C와 IBS-D 증상을 모두 줄입니다. 과도한 가스를 유발하지 않는 내약성 좋은 프리바이오틱입니다. SIBO 관련 증상에도 가능성을 보입니다.
Key Study Findings
Randomized Controlled Trial
n=47
8 weeks
Double-blind
Effects of a polyphenol-rich extract blend, probiotics, and hydrolyzed fiber on quality of life and …
Dose: None
vs: Placebo (Group I) and partial formulation (Group II)
Outcome: IBS quality of life (QoL questionnaire)
효과: Dysphoria: median diff -5 (Group III) vs -1 (contr
0.0021 (dysphoria Group III)
대상 집단: Patients with IBS
Controlled Clinical Trial
Changes in intestinal microbiota and biochemical parameters in patients with inflammatory bowel disease and irritable …
Dose: Partially hydrolyzed guar gum (PHGG)
vs: Drug therapy alone
Outcome: Gut bacteria ratios and inflammatory markers
효과: None
None
대상 집단: Patients with IBD or IBS on drug therapy
Controlled Clinical Trial
12.9 weeks
Role of Baseline Gut Microbiota on Response to Fiber Intervention in Individuals with Irritable Bowel …
Dose: None
vs: baseline
Outcome: IBS symptom improvement
효과: None
None
대상 집단: Ibs undertook a 90-day intervention and follow-up
Case Reports
Fibers in pediatric functional gastrointestinal disorders. Practical considerations from clinical cases.
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: None
Randomized Controlled Trial
13.0 weeks
Double-blind
Effect of Repeated Consumption of Partially Hydrolyzed Guar Gum on Fecal Characteristics and Gut Microbiota: …
Dose: None
vs: Placebo
Outcome: Bowel function
효과: None
p=0.05
대상 집단: healthy volunteers
Randomized Controlled Trial
12 weeks
Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients …
Dose: partially hydrolyzed guar gum (PHGG) 5g/day
vs: placebo
Outcome: IBS-SSS and bloating severity
효과: significant improvement in overall IBS-SSS
<0.05
대상 집단: Adults with IBS
Key Statistics
5
연구
350
참여자
↑
Positive
B
등급
Referenced Papers
Frontiers in nutrition
2025
3 인용
The journal of …
2024
2 인용
Nutrients
2023
3 인용
Fibers in pediatric functional gastrointestinal disorders. Practical considerations from clinical cases.
Case Report
Expert review of …
2021
7 인용
Nutrients
2019
68 인용
Nutrition & metabolism
2016
61 인용
Probiotics for Irritable Bowel Syndrome: Clinical Data in Children.
Systematic Review
Journal of pediatric …
2016
19 인용
Saudi journal of …
2015
32 인용
World journal of …
2013
69 인용
Minerva gastroenterologica e …
2013
Nutrition (Burbank, Los …
2006
119 인용
Digestive diseases and …
2005
55 인용
Nutrition (Burbank, Los …
2003
143 인용
Digestive diseases and …
2002
117 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 5-7 g/day
- ibssupport:
- 5 g/day for 4-12 weeks
- siboadjunct:
- 5 g/day alongside antimicrobial therapy
상한량: Well-tolerated up to 36 g/day in clinical trials
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | 8 weeks | Positive | 47 |
| Partially hydrolyzed guar gum (PHGG) | -- | Positive | -- |
| None | 12.9 weeks | Positive | -- |
| None | -- | Positive | -- |
| None | 13.0 weeks | Mixed | -- |
| partially hydrolyzed guar gum (PHGG) 5g/day | 12 weeks | Positive | -- |
| various probiotic strains | -- | Mixed | -- |
| None | 4.0 weeks | Positive | -- |
권장 복용 시간: Mixed into food or beverages; dissolves completely without altering texture
Safety & Side Effects
보고된 부작용
- ⚠ Minimal gas and bloating (significantly less than other fibers)
- ⚠ Mild abdominal discomfort in rare cases
- ⚠ Loose stools at very high doses
알려진 상호작용
- ● May slow absorption of some medications (space 1-2 hours)
- ● Diabetes medications (may modestly affect blood glucose)
일일 최대 섭취 허용량: Well-tolerated up to 36 g/day in clinical trials
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 부분가수분해 구아검(PHGG) help with 과민성 대장 증후군(IBS)?
Based on 5 studies with 350 participants, there is moderate evidence from clinical studies that 부분가수분해 구아검(PHGG) may support 과민성 대장 증후군(IBS) management. Our evidence grade is B (Good Evidence).
How much 부분가수분해 구아검(PHGG) should I take for 과민성 대장 증후군(IBS)?
Studies have used various dosages. A commonly studied range is 5-7 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 부분가수분해 구아검(PHGG)?
Reported side effects may include Minimal gas and bloating (significantly less than other fibers), Mild abdominal discomfort in rare cases, Loose stools at very high doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 부분가수분해 구아검(PHGG) and 과민성 대장 증후군(IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 5 peer-reviewed studies with 350 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 과민성 대장 증후군(IBS)
부분가수분해 구아검(PHGG) 다른 건강 상태에 대한 근거
References
- [1] Adrianna Wierzbicka et al.. Front Nutr. 2025. Effects of a polyphenol-rich extract blend, probiotics, and hydrolyzed fiber on quality of life and gut health markers in patients … doi:10.3389/fnut.2025.1603011 PubMed
- [2] Hideo Watanabe et al.. J Med Invest. 2024. Changes in intestinal microbiota and biochemical parameters in patients with inflammatory bowel disease and irritable bowel syndrome induced by the … doi:10.2152/jmi.71.121 PubMed
- [3] Jerry Zhou et al.. Nutrients. 2023. Role of Baseline Gut Microbiota on Response to Fiber Intervention in Individuals with Irritable Bowel Syndrome. doi:10.3390/nu15224786 PubMed
- [4] Claudio Romano et al.. Expert Rev Gastroenterol Hepatol. 2021. Fibers in pediatric functional gastrointestinal disorders. Practical considerations from clinical cases. doi:10.1080/17474124.2021.1884543 PubMed
- [5] Zenta Yasukawa et al.. Nutrients. 2019. Effect of Repeated Consumption of Partially Hydrolyzed Guar Gum on Fecal Characteristics and Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled, and … doi:10.3390/nu11092170 PubMed
- [6] E Niv et al.. Nutr Metab (Lond). 2016. Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. doi:10.1186/s12986-016-0070-5 PubMed
- [7] Eleonora Giannetti et al.. J Pediatr Gastroenterol Nutr. 2016. Probiotics for Irritable Bowel Syndrome: Clinical Data in Children. doi:10.1097/MPG.0000000000001220 PubMed
- [8] Luigi Russo et al.. Saudi J Gastroenterol. 2015. Partially hydrolyzed guar gum in the treatment of irritable bowel syndrome with constipation: effects of gender, age, and body mass … doi:10.4103/1319-3767.153835 PubMed
- [9] Claudio Romano et al.. World J Gastroenterol. 2013. Partially hydrolyzed guar gum in pediatric functional abdominal pain. doi:10.3748/wjg.v19.i2.235 PubMed
- [10] G Quartarone. Minerva Gastroenterol Dietol. 2013. Role of PHGG as a dietary fiber: a review article. PubMed
- [11] Edoardo G Giannini et al.. Nutrition. 2006. Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. doi:10.1016/j.nut.2005.10.003 PubMed
- [12] Giancarlo Parisi et al.. Dig Dis Sci. 2005. Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. A … doi:10.1007/s10620-005-2713-7 PubMed
- [13] Joanne L Slavin et al.. Nutrition. 2003. Partially hydrolyzed guar gum: clinical nutrition uses. doi:10.1016/s0899-9007(02)01032-8 PubMed
- [14] G C Parisi et al.. Dig Dis Sci. 2002. High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet … doi:10.1023/a:1016419906546 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.